title: Canalization effect in the coagulation cascade and the interindividual variability of oral anticoagulant response. A simulation study.
abstract: BACKGROUND
  Increasing the predictability and reducing the rate of side effects of oral anticoagulant treatment (OAT) requires further clarification of the cause of about 50% of the interindividual variability of OAT response that is currently unaccounted for. We explore numerically the hypothesis that the effect of the interindividual expression variability of coagulation proteins, which does not usually result in a variability of the coagulation times in untreated subjects, is unmasked by OAT.
  
  
  RESULTS
  We developed a stochastic variant of the Hockin-Mann model of the tissue factor coagulation pathway, using literature data for the variability of coagulation protein levels in the blood of normal subjects. We simulated in vitro coagulation and estimated the Prothrombin Time and the INR across a model population. In a model of untreated subjects a "canalization effect" can be observed in that a coefficient of variation of up to 33% of each protein level results in a simulated INR of 1 with a clinically irrelevant dispersion of 0.12. When the mean and the standard deviation of vitamin-K dependent protein levels were reduced by 80%, corresponding to the usual Warfarin treatment intensity, the simulated INR was 2.98 ± 0.48, a clinically relevant dispersion, corresponding to a reduction of the canalization effect.Then we combined the Hockin-Mann stochastic model with our previously published model of population response to Warfarin, that takes into account the genetical and the phenotypical variability of Warfarin pharmacokinetics and pharmacodynamics. We used the combined model to evaluate the coagulation protein variability effect on the variability of the Warfarin dose required to reach an INR target of 2.5. The dose variance when removing the coagulation protein variability was 30% lower. The dose was mostly related to the pretreatment levels of factors VII, X, and the tissue factor pathway inhibitor (TFPI).
  
  
  CONCLUSIONS
  It may be worth exploring in experimental studies whether the pretreatment levels of coagulation proteins, in particular VII, X and TFPI, are predictors of the individual warfarin dose, even though, maybe due to a canalization-type effect, their effect on the INR variance in untreated subjects appears low.
authors.affiliation: University Emergency Hospital, 169 Spl Independentei, Bucharest, Romania.
authors.forename: Alexandru D
authors.initials: AD
authors.lastname: Corlan
authors.forename: John
authors.initials: J
authors.lastname: Ross
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000378:metabolism; D003198:Computer Simulation; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008954:Models, Biological; D014859:Warfarin / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D000925:Anticoagulants; D001779:Blood Coagulation Factors; D014859:Warfarin
references.citation: Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10528-32
references.pmid: 12082173
references.citation: Thromb Haemost. 2010 Aug;104(2):207-12
references.pmid: 20431849
references.citation: Arterioscler Thromb Vasc Biol. 2000 Feb;20(2):593-600
references.pmid: 10669660
references.citation: Am J Clin Pathol. 2008 Nov;130(5):811-5
references.pmid: 18854275
references.citation: Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6465-70
references.pmid: 19366671
references.citation: Blood. 2009 Apr 23;113(17):3925-30
references.pmid: 19074728
references.citation: Am J Epidemiol. 1996 Apr 1;143(7):665-76
references.pmid: 8651228
references.citation: Clin Chim Acta. 2004 Nov;349(1-2):199-202
references.pmid: 15469874
references.citation: J Atheroscler Thromb. 2010 Apr 30;17(4):402-9
references.pmid: 20379055
references.citation: Ann Hum Genet. 2010 Jan;74(1):34-45
references.pmid: 20059471
references.citation: Eur J Clin Pharmacol. 2007 Dec;63(12):1135-41
references.pmid: 17899045
references.citation: Clin Chem. 2010 Oct;56(10):1608-17
references.pmid: 20798354
references.citation: Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):646-9
references.pmid: 15604416
references.citation: Clin Chem. 2009 Oct;55(10):1861-8
references.pmid: 19679631
references.citation: Thromb J. 2003 Nov 30;1(1):7
references.pmid: 14969588
references.citation: Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4627-32
references.pmid: 18353988
references.citation: Circulation. 2010 Mar 30;121(12):1382-92
references.pmid: 20231535
references.citation: Circulation. 1997 Aug 19;96(4):1102-8
references.pmid: 9286936
references.citation: J Biol Chem. 2002 May 24;277(21):18322-33
references.pmid: 11893748
references.citation: Circulation. 1997 Jul 1;96(1):19-21
references.pmid: 9236409